XML 26 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stockholders' Equity
6 Months Ended
Jun. 25, 2016
Stockholders' Equity  
Stockholders' Equity

9.Stockholders’ Equity

 

The Company’s 2015 Equity Incentive Plan (the “2015 Plan”) was approved at our 2015 annual meeting of stockholders. Under the 2015 Plan, we are authorized to issue up to 1,400,560 shares of our Common Stock, which number may be increased by up to 250,000 shares subject to any option or award outstanding under the 2005 Equity Incentive Plan that are canceled or forfeited for any reason.  If any shares of our Common Stock subject to awards granted under the 2015 Plan are canceled, those shares will be available for future awards under such plan.   Awards granted under the 2015 Plan may include: nonqualified stock options, incentive stock options, restricted stock, restricted stock units, performance shares, performance units, and other stock-based awards and cash-based awards.  The 2015 Plan has a term of ten years and expires in May 2025.  As of June 25, 2016, there were 955,362 shares of Common Stock available for awards under the 2015 Plan.

 

Restricted Common Stock

 

We have issued shares of restricted Common Stock in the form of restricted stock awards and restricted stock units as incentives to certain employees, officers and members of our board of directors (the “Board”).  Restricted stock awards and restricted stock units granted to members of the Board are granted with a one-year service period.  Restricted stock awards and restricted stock units granted to the Company’s officers vest over three years and typically contain performance conditions that are required to be achieved over a three-year measurement period in order for the shares to be released.  The number of performance-based restricted stock awards and units that ultimately vest depend on whether we achieve certain financial results.  Restricted stock units granted to non-officer employees generally vest over three or five years.  We record compensation expense each period based on (i) the market price of our Common Stock at the time of grant and, (ii) for performance-based restricted stock awards and units, our estimate of the most probable number of shares that will ultimately be released.  The related stock-based compensation expense is included in selling, general and administrative expenses.  Additionally, the compensation expense is adjusted for our estimate of forfeitures.  Recipients of restricted Common Stock are entitled to receive any dividends declared on our Common Stock and have voting rights, regardless of whether such shares have vested.

 

During the three months ended June 25, 2016 and June 27, 2015, the total stock-based compensation expense from restricted Common Stock recognized in the financial statements was $0.3 million and $0.3 million, respectively. During the six months ended June 25, 2016 and June 27, 2015, the total stock-based compensation expense from restricted common stock recognized in the financial statements was $0.7 million and $0.5 million, respectively. There were no stock-based compensation costs capitalized. 

 

The following table summarizes activities related to restricted stock awards for the six months ended June 25, 2016:

 

 

 

 

 

 

 

 

 

    

 

    

Weighted

 

 

 

 

 

Average Grant

 

 

 

Number

 

Date Fair Value

 

Nonvested balance at December 26, 2015

 

88,166

 

$

8.25

 

Granted

 

 —

 

$

 —

 

Vested and released

 

(61,163)

 

$

7.96

 

Forfeited

 

(18,670)

 

$

7.20

 

Nonvested balance at June 25, 2016

 

8,333

 

$

12.78

 

 

As of June 25, 2016, the total unrecognized costs related to non-vested restricted stock awards was $0.1 million, which is expected to be recognized over a weighted average period of 0.9 years.  This expected compensation expense does not reflect any new awards, or modifications to existing awards, that could occur in the future.

 

The following table summarizes activities related to restricted stock units for the six months ended June 25, 2016:

 

 

 

 

 

 

 

 

 

 

    

 

    

Weighted

 

 

 

 

 

Average Grant

 

 

 

Number

 

Date Fair Value

 

Nonvested balance at December 26, 2015

 

302,113

 

$

10.40

 

Granted

 

328,368

 

$

7.09

 

Vested and released

 

(76,614)

 

$

10.26

 

Forfeited

 

(10,188)

 

$

11.18

 

Nonvested balance at June 25, 2016

 

543,679

 

$

8.40

 

 

As of June 25, 2016, the total unrecognized costs related to non-vested restricted stock units was $3.4 million, which is expected to be recognized over a weighted average period of 2.2 years.  This expected compensation expense does not reflect any new awards, or modifications to existing awards, that could occur in the future. 

 

Stock Options

 

Stock-based compensation expense from stock options recognized in the financial statements totaled $0.1 and $0.1 million for the three months ended June 25, 2016 and June 27, 2015, respectively. During the six months ended June 25, 2016 and June 27, 2015, stock-based compensation expense from stock options totaled $0.1 million and $0.2 million, respectively.  There were no stock-based compensation costs capitalized.

 

The following table summarizes stock option activity during the six months ended June 25, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

    

 

 

    

Aggregate

    

Weighted Average

 

 

 

 

 

Weighted

 

Intrinsic Value

 

Remaining

 

 

 

Options

 

Average

 

(in-the-money

 

Contractual Life

 

 

 

Outstanding

 

Exercise Price

 

options)

 

(in years)

 

Outstanding at December 26, 2015

 

644,602

 

$

5.30

 

 

 

 

 

 

Granted

 

 —

 

$

 —

 

 

 

 

 

 

Exercised

 

(38,000)

 

$

4.92

 

 

 

 

 

 

Forfeited or expired

 

(39,000)

 

$

6.67

 

 

 

 

 

 

Outstanding at June 25, 2016

 

567,602

 

$

5.23

 

$

1,574,972

 

4.92

 

 

As of June 25, 2016, the total unrecognized costs related to non-vested stock options granted were $0.3 million.  We expect to recognize such costs in the financial statements over a weighted average period of 1.8 years.  This expected compensation expense does not reflect any new awards, or modifications to existing awards, that could occur in the future. 

 

The aggregate intrinsic value in the preceding table represents the total pre-tax intrinsic value, based on the closing price of $7.55 of our Common Stock as of June 25, 2016, which would have been received by the option holders had all option holders exercised options and sold the underlying shares on that date.  The intrinsic value related to vested stock options outstanding was $1.5 million as of June 25, 2016 based on the exercise price and closing price of $7.55 of our Common Stock as of June 25, 2016.

 

The following table summarizes information about stock options outstanding and exercisable at June 25, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

    

Weighted

    

 

 

    

 

    

 

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remaining

 

Weighted

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

Contractual

 

Average

 

 

 

Average

 

Range of

 

Options

 

Life

 

Exercise

 

Options

 

Exercise

 

Exercise Prices

 

Outstanding

 

(in years)

 

Price

 

Exercisable

 

Price

 

$

1.70

-

$

2.40

 

173,600

 

2.4

 

$

1.88

 

173,600

 

$

1.88

 

$

3.44

-

$

6.55

 

218,550

 

5.1

 

$

5.04

 

198,250

 

$

4.88

 

$

7.21

-

$

12.78

 

153,800

 

7.0

 

$

8.17

 

92,600

 

$

7.89

 

$

13.21

-

$

13.21

 

21,652

 

8.0

 

$

13.21

 

21,652

 

$

13.21

 

 

 

 

 

 

 

567,602

 

4.9

 

$

5.23

 

486,102

 

$

4.75

 

 

 

Prior to May 2008, all stock option grants had a five-year term.  The fair value of these stock option grants is amortized to expense over the service period, generally five years for employees and one year for members of the Board.  In May 2008, our Board approved a 10-year term for all future stock option grants, with service periods of five years for employees and one year for members of the Board.  We issue new shares upon the exercise of stock options, as opposed to reissuing treasury shares.